DHT Holdings, Inc. Business Update
April 11, 2024 16:15 ET
|
DHT Holdings, Inc.
HAMILTON, BERMUDA, April 11, 2024 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: For the first quarter of 2024, the Company estimates time...
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024 08:00 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new...
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
April 09, 2024 01:00 ET
|
ONWARD Medical NV
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024 08:45 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
BioCorRx Reports Business Update for 2023
April 02, 2024 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
March 27, 2024 12:45 ET
|
Transgene S.A.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity...
Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
March 27, 2024 12:45 ET
|
Transgene S.A.
Résultats annuels 2023 et point sur l’activité TG4050 : de nouveaux résultats attendus en 2024 sur l’actif phare de TransgeneLes autres programmes cliniques et de recherche et innovation...
Evaxion Announces Business Update and Full Year 2023 Financial Results
March 27, 2024 07:30 ET
|
Evaxion Biotech
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...
DHT Holdings, Inc. Business Update
January 17, 2024 16:15 ET
|
DHT Holdings, Inc.
HAMILTON, BERMUDA, January 17, 2024 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: The Company estimates its P&L break-even level for the...
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
January 16, 2024 16:01 ET
|
Celyad Oncology SA
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...